Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-10-07

FDA Approved: EMPAVELI — Supplemental Application (Apellis Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for EMPAVELI (pegcetacoplan) submitted by Apellis Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EMPAVELI (pegcetacoplan)

Snippet

SUPPL AP for EMPAVELI (PEGCETACOPLAN)